Sara M. Tolaney

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

83h-index35.1kcitations1.3kworks3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(542), HER2/EGFR in Cancer Research(449), Cancer Treatment and Pharmacology(325), Breast Cancer Treatment Studies(266), Cancer Immunotherapy and Biomarkers(214)

Publications1.3k total

A Phase Ib Study of Sapacitabine and Olaparib in Patients with <i>BRCA1/2-</i> Mutated Metastatic Breast Cancer
Clinical Cancer Research·2025
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
UNC Libraries·2025Open Access
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer
Nature Communications·2025· 2 citedOpen Access
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
Nature Communications·2025· 1 citedOpen Access
Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 2 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 6 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 1 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 4 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
2025Open Access
page 1 of 66Next →

Frequent Co-authors

Eric P. Winer(15), Hope S. Rugo(14), Ian E. Krop(11), Nancy U. Lin(9), Javier Cortés(8), Aditya Bardia(7), Lisa A. Carey(7), Giuseppe Curigliano(7), Nikhil Wagle(7), Romualdo Barroso‐Sousa(7), Clifford A. Hudis(6), Paolo Tarantino(6), Adrienne G. Waks(5), William T. Barry(5), Steven J. Isakoff(5), Denise A. Yardley(5), Harold J. Burstein(5), Melissa E. Hughes(5), Delphine Loirat(4), Kevin Kalinsky(4)